Andrew Buckland

Biography

Andrew Buckland has extensive experience in the development of financial operations within both large multinational corporations and early to mid-stage companies. He has a diverse background in international business as well as over fifteen years as the most senior financial officer of U.S. public and pre-IPO life sciences companies. Since 2012, Mr. Buckland has been the Chief Financial Officer of San Diego-based Polynoma LLC. In this role, he is responsible for all finance, accounting, treasury, human resources, information technology and risk management functions for a biotechnology company developing an immunotherapy for the treatment of melanoma, currently running one of the world’s largest global Phase III melanoma clinical trials. Like WEX, Polynoma is also a subsidiary of CK Life Sciences Int’l (Holdings), Inc. Prior to his tenure at Polynoma, Mr. Buckland served as Chief Financial Officer of PURE Bioscience, Inc., a company he took from the OTC Bulletin Board to the NASDAQ Stock Market. Prior to PURE Bioscience, Mr. Buckland served as Vice President of Finance at Cardionet, Inc., as Chief Financial Officer of Advanced Tissue Sciences, Inc., a NASDAQ-listed public biotechnology company, and in significant international accounting and financial management positions at Bristol-Myers Squibb and United Parcel Service. He has completed several private placements and registered direct common stock offerings in the United States, and obtained SEC effectiveness on multiple registration statements. Mr. Buckland earned an MBA from the University of California, Irvine and a BA (with Honors) from the University of the West of England.

Research Interest

Business and Management